Q2 2021 Earnings Estimate for Inovio Pharmaceuticals, Inc. Issued By Piper Sandler (NASDAQ:INO)

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) – Investment analysts at Piper Sandler decreased their Q2 2021 earnings per share estimates for Inovio Pharmaceuticals in a research report issued on Monday, May 10th. Piper Sandler analyst C. Raymond now expects that the biopharmaceutical company will post earnings per share of ($0.26) for the quarter, down from their prior estimate of ($0.17). Piper Sandler currently has a “Neutral” rating and a $6.00 target price on the stock. Piper Sandler also issued estimates for Inovio Pharmaceuticals’ Q3 2021 earnings at ($0.26) EPS, Q4 2021 earnings at ($0.27) EPS, FY2021 earnings at ($1.06) EPS, Q1 2022 earnings at ($0.25) EPS, Q2 2022 earnings at ($0.26) EPS, Q3 2022 earnings at ($0.26) EPS, Q4 2022 earnings at ($0.27) EPS, FY2022 earnings at ($1.05) EPS, FY2023 earnings at ($0.67) EPS, FY2024 earnings at ($0.23) EPS and FY2025 earnings at $0.12 EPS.

Inovio Pharmaceuticals (NASDAQ:INO) last posted its earnings results on Monday, May 10th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.09). The company had revenue of $0.40 million during the quarter, compared to the consensus estimate of $1.06 million. Inovio Pharmaceuticals had a negative net margin of 8,518.10% and a negative return on equity of 78.17%. The company’s revenue for the quarter was down 69.2% compared to the same quarter last year.

INO has been the topic of a number of other reports. Zacks Investment Research lowered Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday. Oppenheimer reissued a “buy” rating on shares of Inovio Pharmaceuticals in a report on Friday, April 16th. HC Wainwright reissued a “hold” rating on shares of Inovio Pharmaceuticals in a report on Friday, April 16th. Finally, Bank of America initiated coverage on Inovio Pharmaceuticals in a report on Monday, March 29th. They set a “neutral” rating and a $13.00 price target on the stock. Two analysts have rated the stock with a sell rating, five have issued a hold rating and three have issued a buy rating to the stock. Inovio Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $15.78.

INO stock opened at $6.55 on Thursday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 9.14 and a current ratio of 9.14. The stock has a market capitalization of $1.37 billion, a price-to-earnings ratio of -4.82 and a beta of 1.08. Inovio Pharmaceuticals has a 1 year low of $5.81 and a 1 year high of $33.79. The stock’s fifty day moving average is $8.03 and its two-hundred day moving average is $10.22.

In related news, CFO Peter Kies sold 10,000 shares of the stock in a transaction on Wednesday, April 21st. The stock was sold at an average price of $8.52, for a total value of $85,200.00. Following the completion of the transaction, the chief financial officer now owns 160,788 shares in the company, valued at approximately $1,369,913.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Jacqueline Elizabeth Shea sold 16,881 shares of the stock in a transaction on Friday, March 12th. The shares were sold at an average price of $10.06, for a total value of $169,822.86. Following the completion of the transaction, the chief operating officer now owns 98,272 shares of the company’s stock, valued at approximately $988,616.32. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 69,174 shares of company stock worth $629,138. 4.00% of the stock is owned by corporate insiders.

Several large investors have recently added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc. boosted its position in Inovio Pharmaceuticals by 1.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,095,477 shares of the biopharmaceutical company’s stock worth $9,695,000 after acquiring an additional 19,369 shares during the period. Greenwich Wealth Management LLC acquired a new stake in Inovio Pharmaceuticals during the 4th quarter worth about $107,000. Pacer Advisors Inc. boosted its position in Inovio Pharmaceuticals by 48.2% during the 4th quarter. Pacer Advisors Inc. now owns 11,967 shares of the biopharmaceutical company’s stock worth $106,000 after acquiring an additional 3,894 shares during the period. International Assets Investment Management LLC acquired a new stake in Inovio Pharmaceuticals during the 4th quarter worth about $96,000. Finally, Schonfeld Strategic Advisors LLC acquired a new stake in Inovio Pharmaceuticals during the 3rd quarter worth about $118,000. Institutional investors and hedge funds own 35.96% of the company’s stock.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon optimized plasmids that have ability to help break the immune system's tolerance of cancerous or infected cells and facilitate cross-strain protection against unmatched and matched pathogen variants.

Further Reading: The Discount Rate – What You Need to Know

Earnings History and Estimates for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.